Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- AnGes MG Obtains Exclusive Rights for Vaccine for Precancerous Condition of the Cervix in China
June 28, 2012
- Takeda Ranked No. 1 in Medical Category for 5th Year in a Row: Popularity Rankings for Career Change
June 28, 2012
- DSP Launches Myslee Generic on June 28
June 28, 2012
- Eisai to Make Full-Scale Entry into Russian Market; Antiepileptic Agent Obtains Approval
June 28, 2012
- Yoshindo to Accumulate Know-How to Develop Biopharmaceutical Products through Contract Manufacturing
June 28, 2012
- Astellas Files MAA for Anti-Androgen Agent MDV3100 in Europe
June 28, 2012
- Chugai Applies for Tarceva for NSCLC First-Line Therapy
June 28, 2012
- Takata Seiyaku to Market 3 Products from Shionogi
June 28, 2012
- MSs Want “Client Visits by MRs” for Generic Promotion: Toho Pharmaceutical Survey
June 27, 2012
- Large Number of GEs Could Become Serious Issue: Alfresa Logistics Chief Fukujin
June 27, 2012
- Takeda to Market Iron Deficiency Anemia Drug in Europe
June 27, 2012
- DSP to Ship Almarl under New Brand Name from Mid-July
June 27, 2012
- Azilva Ranks No. 1 Both in GP, HP Market in May: Rep Track Survey
June 27, 2012
- Astellas Launches Kiklin Capsules, Copromotes with SKK
June 26, 2012
- ACE Inhibitors Approved for Pediatric Use: MSD, AZ, Shionogi, Kyowa Pharmaceutical
June 26, 2012
- Amlodipine Besylate Approved for Supplemental Indication of Pediatric Hypertension, Generic Versions also Approved
June 26, 2012
- Pfizer Remains Top, Takeda Ranks 12th in World Ranking in FY2011
June 26, 2012
- EvaluatePharma Forecasts Januvia to Become World’s Best-Selling Product in 2018
June 25, 2012
- RaQualia Receives Substance Patent Evaluation in US for 5-HT2B Antagonist
June 25, 2012
- Otsuka, UCB Japan Apply for E Keppra for Pediatric Epilepsy
June 25, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…